CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.82BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
146.97%vs all stocks
Market Capitalization
1.82BUSDvs all stocks (USD)
Enterprise Value
1.29BUSDvs all stocks (USD)
Forward P/E
-7.64xvs Biotechnology peers
Price to Book (MRQ)
3.54xvs Biotechnology peers
Enterprise to EBITDA
-7.39xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-21.09%vs Biotechnology peers
Return on Equity (TTM)
-32.34%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-173.93MUSDvs all stocks (USD)
Net Income (TTM)
-157.32MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-116.24MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-68.39MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-155.60MUSDvs all stocks (USD)
Pre-tax Income
-137.73MUSDFY2025 · Dec 31, 2025Income Tax Expense
217.00KUSDFY2025 · Dec 31, 2025Net Income
-137.95MUSDFY2025 · Dec 31, 2025EBIT
-155.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-155.50MUSDFY2025 · Dec 31, 2025Research & Development
125.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
30.51MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
17.87MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.52USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.52USDFY2025 · Dec 31, 2025Basic Shares Outstanding
54.68MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
54.68MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-137.95MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-122.88MUSDFY2025 · Dec 31, 2025Free Cash Flow
-123.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
96.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-137.95MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
105.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
15.01MUSDFY2025 · Dec 31, 2025Other Non-cash Items
895.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-932.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-280.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-318.17MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-318.45MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
29.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
65.55MSharesUpdated Jul 18, 2026Float Shares
36.68MSharesUpdated Jul 18, 2026Shares Short
10.12MSharesUpdated Jul 18, 2026Short Ratio
10.80daysvs all stocks
Short % of Shares Outstanding
21.52%vs all stocks
% Held by Insiders
10.14%vs all stocks
% Held by Institutions
104.36%vs all stocks
Total Cash (MRQ)
539.75MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.21USDUpdated Jul 18, 2026Total Debt (MRQ)
1.44MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0028xvs Biotechnology peers
Current Ratio (MRQ)
13.85xvs Biotechnology peers
Book Value per Share (MRQ)
7.84USDUpdated Jul 18, 2026Total Assets
430.99MUSDvs all stocks (USD)
Total Current Assets
422.05MUSDFY2025 · Dec 31, 2025Total Liabilities
29.54MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.94MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
593.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
28.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
96.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
318.12MUSDFY2025 · Dec 31, 2025Accounts Payable
7.79MUSDFY2025 · Dec 31, 2025Short-term Debt
1.12MUSDFY2025 · Dec 31, 2025Long-term Debt
593.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-358.97MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
401.45MUSDvs all stocks (USD)
52-Week Low
9.57USDUpdated Jul 18, 202652-Week High
30.99USDUpdated Jul 18, 202652-Week Change
146.97%vs all stocks
50-Day MA
23.85USDUpdated Jul 18, 2026200-Day MA
19.44USDUpdated Jul 18, 2026Avg 10-Day Volume
654.77KSharesUpdated Jul 18, 2026Avg 30-Day Volume
869.46KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.79USDUpdated Jul 18, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.57
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.82B, above the global median of $1.15BNotable
Market cap (USD): 1,823,939,320Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sarepta Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule